Intensive management of hepatic failure

Seminars in Respiratory and Critical Care Medicine

Volumn 27, Issue 3, 2006, Pages 241-261

  Rinella, Mary E ^a   Sanyal, Arun ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral edema; Liver failure; Management; Portal hypertension

Indexed keywords

ACETYLCYSTEINE; ACICLOVIR; ALBUMIN; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEFOTAXIME; CORTICOSTEROID; DESMOPRESSIN; DIURETIC AGENT; HETASTARCH; INDOMETACIN; LACTULOSE; MANNITOL; NEOMYCIN; NORFLOXACIN; OCTREOTIDE; PARACETAMOL; PENICILLIN G; RIFAXIMIN; SILIBININ; SODIUM CHLORIDE; SOMATOSTATIN; TERLIPRESSIN; THIOPENTAL; VASOPRESSIN; ZINC SULFATE;

ADRENAL CORTEX INSUFFICIENCY; AMANITA PHALLOIDES; ARTIFICIAL VENTILATION; ASCITES; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BLEEDING; BRAIN EDEMA; BUDD CHIARI SYNDROME; CRITICALLY ILL PATIENT; DEVICE; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS VARICES BLEEDING; FATTY LIVER; HELLP SYNDROME; HEMOSTASIS; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATORENAL SYNDROME; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HYPERVENTILATION; INDUCED HYPOTHERMIA; INTENSIVE CARE UNIT; INTRACRANIAL HYPERTENSION; JAUNDICE; KIDNEY FAILURE; LIGATION; LIVER ASSIST DEVICE; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MULTIPLE ORGAN FAILURE; MUSHROOM POISONING; PARACENTESIS; PORTAL HYPERTENSION; PORTAL HYPERTENSIVE GASTROPATHY; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; REVIEW; SEPSIS; STOMACH DISEASE; STOMACH VARICES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TAMPON; WILSON DISEASE;

BRAIN EDEMA; ESOPHAGEAL AND GASTRIC VARICES; HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERTENSION, PORTAL; INTENSIVE CARE; INTENSIVE CARE UNITS; INTRACRANIAL PRESSURE; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; RISK ASSESSMENT;

EID: 33745957764     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-945528     Document Type: Review

References (220)

1. Trey C, Lipworth L, Davidson CS. Halothane and liver damage. N Engl J Med 1969;280:562-563
2. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis 1970;3:282-298
3. Bernal W, Wendon J. Liver transplantation in adults with acute liver failure. J Hepatol 2004;40:192-197
4. Blei AT. Medical therapy of brain edema in fulminant hepatic failure. Hepatology 2000;32:666-669
5. Mas A, Rodes J. Fulminant hepatic failure. Lancet 1997;349: 1081-1085
6. Larsen FS, Wendon J. Brain edema in liver failure: basic physiologic principles and management. Liver Transpl 2002; 8:983-989
7. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-446
8. Izumi S, Langley PG, Wendon J, et al. Coagulation factor V levels as a prognostic indicator in fulminant hepatic failure. Hepatology 1996;23:1507-1511
9. Pereira LM, Langley PG, Hayllar KM, Tredger JM, Williams R. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators. Gut 1992;33:98-102
10. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003;23:217-226
11. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med 1986;104:399-404
12. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiaty care centers in the United States. Ann Intern Med 2002;137:947-954
13. Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology 1995;109:1907-1916
14. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995;22: 767-773
15. Schiodt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997;337:1112-1117
16. McClain CJ, Kromhout JP, Peterson FJ, Holtzman JL. Potentiation of acetaminophen hepatotoxicity by alcohol. JAMA 1980;244:251-253
17. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med 1990;113:799-800
18. Prescott LF, Critchley JA. The treatment of acetaminophen poisoning. Annu Rev Pharmacol Toxicol 1983;23:87-101
19. Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology 2004;40:6-9
20. Harrison PM, Keays R, Bray GP, Alexander GJ, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990;335:1572-1573
21. Donaldson BW, Gopinath R, Wanless IR, et al. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. Hepatology 1993;18:1370-1376
22. Chung PY, Sitrin MD, Te HS. Serum phosphorus levels predict clinical outcome in fulminant hepatic failure. Liver Transpl 2003;9:248-253
23. Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005;41:26-31
24. Baquerizo A, Anselmo D, Shackleton C, et al. Phosphorus as an early predictive factor in patients with acute liver failure. Transplantation 2003;75:2007-2014
25. Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003;9:138-143
26. Bernal W. Intensive care support therapy. Liver Transpl 2003;9(suppl 9):S15-S17
27. Vaquero J, Chung C, Cahill ME, Blei AT. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis 2003;23:259-269
28. Vaquero J, Blei AT. Etiology and management of fulminant hepatic failure. Curr Gastroenterol Rep 2003;5:39-47
29. Wijdicks EF, Nyberg SL. Propofol to control intracranial pressure in fulminant hepatic failure. Transplant Proc 2002; 34:1220-1222
30. Steinberg KP. Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. Crit Care Med 2002; 30(Suppl 6):S362-S364
31. Jalan R. Intracranial hypertension in acute liver failure: pathophysiological basis of rational management. Semin Liver Dis 2003;23:271-282
32. Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis 1996;16:379-388
33. Trewby PN, Williams R. Pathophysiology of hypotension in patients with fulminant hepatic failure. Gut 1977;18:1021-1026.
34. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32(4 Pt 1): 734-739
35. Bouachour G, Tirot P, Varache N, Gouello JP, Harry P, Alquier P. Hemodynamic changes in acute adrenal insufficiency. Intensive Care Med 1994;20:138-141
36. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-650
37. McCashland TM, Shaw BW Jr, Tape E. The American experience with transplantation for acute liver failure. Semin Liver Dis 1996;16:427-433
38. Davies MH, Mutimer D, Lowes J, Elias E, Neuberger J. Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet 1994;343:1329-1330
39. Wyke RJ, Yousif-Kadaru AG, Rajkovic IA, Eddleston AL, Williams R. Serum stimulatory activity and polymorpho-nuclear leucocyte movement in patients with fulminant hepatic failure. Clin Exp Immunol 1982;50:442-449
40. Wyke RJ, Rajkovic IA, Eddleston AL, Williams R. Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure. Gut 1980;21: 643-649
41. Altin M, Hughes RD, Williams R. Neutrophil adherence during hemoperfusion in fulminant hepatic failure. Int J Artif Organs 1982;5:315-317
42. Clapperton M, Rolando N, Sandoval L, Davies E, Williams R. Neutrophil Superoxide and hydrogen peroxide production in patients with acute liver failure. Eur J Clin Invest 1997; 27:164-168
43. Rolando N, Harvey F, Brahm J, et al. Prospective study of bacterial infection in acute Ever failure: an analysis of fifty patients. Hepatology 1990;11:49-53
44. Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis 1996; 16:389-402
45. Wade J, Rolando N, Philpott-Howard J, Wendon J. Timing and aetiology of bacterial infections in a liver intensive care unit. J Hosp Infect 2003;53:144-146
46. Rolando N, Gimson A, Wade J, Philpott-Howard J, Casewell M, Williams R. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology 1993;17:196-201
47. Salmeron JM, Tito L, Rimola A, et al. Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure. J Hepatol 1992;14:280-285
48. Rolando N, Wade JJ, Stangou A, et al. Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure. Liver Transpl Surg 1996;2:8-13
49. Vaquero J, Poison J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003;125:755-764
50. Billiau A, Vandekerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest 1991;21:559-573
51. Jalan R, Pollok A, Shah SH, Madhavan K, Simpson KJ. Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure. J Hepatol 2002;37:536-538
52. Bihari DJ, Gimson AE, Williams R. Cardiovascular, pulmonary and renal complications of fulminant hepatic failure. Semin Liver Dis 1986;6:119-128
53. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-732
54. Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002;36:395-402
55. Davenport A, Will EJ, Davison AM, et al. Changes in intracranial pressure during haemofiltration in oliguric patients with grade IV hepatic encephalopathy. Nephron 1989;53:142-146
56. Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993;21:328-338
57. Davenport A, Will EJ, Davison AM. Continuous vs. intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema. Contrib Nephrol 1991;93:225-233
58. O'Grady JG. Paracetamol hepatotoxiciry. how to prevent. J R Soc Med 1997;90:368-370
59. Blei AT, Hypothermia for hypertension. Lancet 1999; (9195):2082
60. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999;29:648-653
61. Strauss GI, Knudsen GM, Kondrup J, Moller K, Larsen FS. Cerebral metabolism of ammonia and amino acids in patients with fulminant hepatic failure. Gastroenterology 2001;121: 1109-1119
62. Strauss GI, Christiansen M, Moller K, Clemmesen JO, Larsen FS, Knudsen GM. S-100b and neuron-specific enolase in patients with fulminant hepatic failure. Liver Transpl 2001;7:964-970
63. Keays RT, Alexander GJ, Williams R. The safety and value of extradural intracranial pressure monitors in fulminant hepatic failure. J Hepatol 1993;18:205-209
64. Lidofsky SD, Bass NM, Prager MC, et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 1992;16:1-7
65. Donovan JP, Shaw BW Jr, Langnas AN, Sorrell MF. Brain water and acute liver failure: the emerging role of intracranial pressure monitoring. Hepatology 1992;16:267-268
66. Larsen FS, Knudsen GM, Hansen BA. Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure: tailored cerebral oxygen utilization. J Hepatol 1997;27:231-238
67. Toftengi F, Larsen FS. Management of patients with fulminant hepatic failure and brain edema. Metab Brain Dis 2004;19:207-214
68. Blei AT, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993;341:157-158
69. Vaquero J, Blei A, Fontana RJ, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005; 12:1581-1589
70. Cordoba J, Blei AT. Cerebral edema and intracranial pressure monitoring. Liver Transpl Surg 1995;1:187-194
71. Caldwell SH, Chang C, Macik BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology 2004;39:592-598
72. Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004;39:464-470
73. Clemmesen JO, Kondrup J, Nielsen LB, Larsen FS, Ott P. Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure. Am J Gastroenterol 2001;96:1217-1223
74. Awad SS, Swaniker F, Magee J, Punch J, Bartlett RH. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001;130:354-362
75. Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 1999;30:636-640
76. Canalese J, Gimson AE, Davis C, Mellon PJ, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 1982;23:625-629
77. Ede RJ, Gimson AE, Bihari D, Williams R. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 1986;2:43-51
78. Strauss GI, Moller K, Holm S, Sperling B, Knudsen GM, Larsen FS. Transcranial Doppler sonography and internal jugular bulb saturation during hyperventilation in patients with fulminant hepatic failure. Liver Transpl 2001;7:352-358
79. Strauss G, Hansen BA, Knudsen GM, Larsen FS. Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure. J Hepatol 1998;28:199-203
80. Jensen K, Ohrstrom J, Cold GE, Astrup J. Indomethacin (Confortid) in severe head injury and elevated intracranial pressure (ICP). Acta Neurochir Suppl (Wien) 1992;55:47-48
81. Chung C, Gottstein J, Blei AT. Indomethacin prevents the development of experimental ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology 2001;34: 249-254
82. Tofteng F, Larsen FS. The effect of indomethacin on intracranial pressure, cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure. J Cereb Blood Flow Metab 2004; 24:798-804
83. Forbes A, Alexander GJ, O'Grady JG, et al. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. Hepatology 1989; 10:306-310
84. Peignoux M, Bernuau J, Benhamou JP. Total hepatectomy and hepatic vascular exclusion in the rat: a comparison, with special reference to the influence of body temperature. Clin Sci (Lond) 1982;62:273-277
85. Eguchi S, Kamlot A, Ljubimova J, et al. Fulminant hepatic failure in rats: survival and effect on blood chemistry and liver regeneration. Hepatology 1996;24:1452-1459
86. Jalan R, Damink SW, Deutz NE, Lee A, Hayes PC. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet 1999;354:1164-1168
87. Jalan R, Olde Damink SW, Deutz NE, et al. Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation for acute liver failure. Transplantation 2003;75:2034-2039
88. Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 2004;127:1338-1346
89. Bernuau J. Acute liver failure: avoidance of deleterious cofactors and early specific medical therapy for the liver are better than late intensive care for the brain. J Hepatol 2004;41:152-155
90. Munoz SJ. Hypothermia may impair hepatic regeneration in acute liver failure. Gastroenterology 2005;128:1143-1144 author reply 1144-1145
91. Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology 1993;17:258-265
92. Sussman NL, Kelly JH. Extracorporeal liver support: cell-based therapy for the failing liver. Am J Kidney Dis 1997;30(5, Suppl 4):S66-S71
93. Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660-667 discussion 667-670
94. Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446-1451
95. Jalan R, Sen S, Williams R. Prospects for extracorporeal liver support. Gut 2004;53:890-898
96. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J 1993;39:M621-M625
97. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993;17: 809-813
98. Stange J, Mitzner SR, Klammt S, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl 2000;6:603-613
99. Lutkes P, Lutz J, Loock J, et al. Continuous venovenous hemodialysis treatment in critically ill patients after liver transplantation. Kidney Int Suppl 1999;(72):S71-S74
100. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-286
101. Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004;10:1099-1106
102. Sen SSC, Williams R. Artificial liver support: overview of registry and controlled trials. In: Arroyo VFX, Garcia-Pagan JC, eds. Progress in the Treatment of Liver Diseases. Barcelona: Ars Medica; 2003:429-435
103. Singh N, Gayowski T, Wagener MM, Marino IR. Outcome of patients with cirrhosis requiring intensive care unit support: prospective assessment of predictors of mortality. J Gastroenterol 1998;33:73-79
104. Kress JP, Rubin A, Pohlman AS, Hall JB. Outcomes of critically ill patients denied consideration for liver transplantation. Am J Respir Crit Care Med 2000;162(2 Pt 1):418-423
105. Zimmerman JE, Wagner DP, Seneff MG, Becker RB, Sun X, Knaus WA Intensive care unit admissions with cirrhosis: risk-stratifying patient groups and predicting individual survival. Hepatology 1996;23:1393-1401
106. Aggarwal A, Ong JP, Younossi ZM, Nelson DR, Hoffman-Hogg L, Arroliga AC. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest 2001;119:1489-1497
107. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157
108. Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 1989;96:1552-1559
109. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-1407
110. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988;319:983-989
111. Mahl TC, Groszmann RJ. Pathophysiology of portal hypertension and variceal bleeding. Surg Clin North Am 1990;70:251-266
112. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-424
113. Vorobioff J, Groszmann RJ, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996;111:701-709
114. Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626-631
115. Grace ND, Groszmann RJ, Garcia-Tsao G, et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998;28:868-880
116. Rossle M. Prevention of rebleeding from oesophageal-gastric varices. Eur J Gastroenterol Hepatol 2001;13:343-348
117. Escorsell A, Bordas JM, Castaneda B, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000;31:1061-1067
118. Chalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol 2003;98:653-659
119. Benoit JN, Womack WA, Korthuis RJ, Wilborn WH, Granger DN. Chronic portal hypertension: effects on gastrointestinal blood flow distribution. Am J Physiol 1986; 250(4 Pt 1):G535-G539
120. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-809
121. Kravetz D, Bosch J, Arderiu M, Pilar Pizcueta M, Rodes J. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting. Hepatology 1989;9:808-814
122. Kruskall MS, Mintz PD, Bergin JJ, et al. Transfusion therapy in emergency medicine. Ann Emerg Med 1988;17: 327-335
123. D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis: posttherapeutic outcome and prognostic indicators. Hepatology 2003;38:599-612
124. El-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000;95:3566-3573
125. Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 2003;17:53-64
126. Escorsell A, Ruiz del Arbol L, Planas R, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 2000;32:471-476
127. Watanabe K, Kimura K, Matsutani S, Ohto M, Okuda K. Portal hemodynamics in patients with gastric varices: a study in 230 patients with esophageal and/or gastric varices using portal vein catheterization. Gastroenterology 1988;95:434-440
128. Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992;16:1343-1349
129. Kim T, Shijo H, Kokawa H, et al. Risk factors for hemorrhage from gastric fundal varices. Hepatology 1997;25:307-312
130. Ohnishi K, Sato S, Saito M, et al. Clinical and portal hemodynamic features in cirrhotic patients having a large spontaneous splenorenal and/or gastrorenal shunt. Am J Gastroenterol 1986;81:450-455
131. Rinella ME, Shah D, Vogelzang RL, Blei AT, Flamm SL. Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis. Gastrointest Endosc 2003;58: 122-127
132. Thakeb F, Salem SA, Abdallah M, el Batanouny M. Endoscopic diagnosis of gastric varices. Endoscopy 1994; 26:287-291
133. Sarin SK, Govil A, Jain AK, et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997;26:826-832
134. Sarin SK, Jain AK, Jain M, Gupta R. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol 2002;97:1010-1015
135. Lo GH, Lai KH, Cheng JS, Chen MH, Chiang HT. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001;33:1060-1064
136. Gallet B, Zemour G, Saudemont JP, Renard P, Hillion ML, Hiltgen M. Echocardiographic demonstration of intracardiac glue after endoscopic obturation of gastroesophageal varices. J Am Soc Echocardiogr 1995;8(5 Pt 1):759-761
137. Rickman OB, Utz JP, Aughenbaugh GL, Gostout CJ. Pulmonary embolization of 2-octyl cyanoacrylate after endoscopic injection therapy for gastric variceal bleeding. Mayo Clin Proc 2004;79:1455-1458
138. See A, Florent C, Lamy P, Levy VG, Bouvry M. Cerebrovascular accidents after endoscopic obturation of esophageal varices with isobutyl-2-cyanoacrylate in 2 patients. Gastroenterol Clin Biol 1986;10:604-607
139. Yang WL, Tripathi D, Therapondos G, Todd A, Hayes PC. Endoscopic use of human thrombin in bleeding gastric varices. Am J Gastroenterol 2002;97:1381-1385
140. Yoshida T, Harada T, Shigemitsu T, Takeo Y, Miyazaki S, Okita K. Endoscopic management of gastric varices using a detachable snare and simultaneous endoscopic sclerotherapy and O-ring ligation. J Gastroenterol Hepatol 1999;14:730-735
141. Yoshida T, Hayashi N, Suzumi N, et al. Endoscopic ligation of gastric varices using a detachable snare. Endoscopy 1994;26:502-505
142. Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 1996;11:51-58
143. Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol 2001;12:327-336
144. Sanyal AJ. The use and misuse of transjugular intrahepatic portasystemic shunts. Curr Gastroenterol Rep 2000;2:61-71
145. Chau TN, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK. "Salvage" transjugular intrahepatic portosystemic shunts: gastric fondal compared with esophageal variceal bleeding. Gastroenterology 1998;114:981-987
146. Henderson JM. Role of distal splenorenal shunt for longterm management of variceal bleeding. World J Surg 1994; 18:205-210
147. Merli M, Salerno F, Riggio O, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio Trends Pharmacol Sci (G.I.S.T.). Hepatology 1998;27:48-53
148. Zhou JH, Liu CY, Zhang RH, Wang HR, Liu KJ. Effects of octreotide on gallbladder pressure and myoelectric activity of Oddi sphincter in rabbits. World J Gastroenterol 1998;4: 238-241
149. Garcia N, Sanyal AJ. Portal hypertensive gastropathy and gastric antral vascular ectasia. Curr Treat Options Gastroenterol 2001;4:163-171
150. Kamath PS, Lacerda M, Ahlquist DA, McKusick MA, Andrews JC, Nagorney DA. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology 2000;118:905-911
151. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004;127:1123-1130
152. Jenkins SA, Shields R, Davies M, et al. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997;41:526-533
153. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001;120:161-169
154. Besson I, Ingrand P, Person B, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995;333:555-560
155. Sung JJ, Chung SC, Yung MY, et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995;346:1666-1669
156. Conn HO, Ramsby GR, Storer EH, et al. Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective, controlled clinical trial. Gastroenterology 1975;68:211-221
157. Bosch J, Groszmann RJ, Garcia-Pagan JC, et al. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. Hepatology 1989;10:962-968
158. Gimson AE, Westaby D, Hegarty J, Watson A, Williams R. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology 1986;6:410-413
159. Soderlund C, Magnusson I, Torngren S, Lundell L. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 1990;25:622-630
160. Garcia-Compean D, Blanc P, Bories JM, et al. Treatment of active gastroesophageal variceal bleeding with terlipressin or hemostatic balloon in patients with cirrhosis: a randomized controlled trial. Arch Med Res 1997;28:241-245
161. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med 1995;123:280-287
162. Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992;326:1527-1532
163. Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999;340:988-993
164. Sarin SK, Guptan RK, Jain AK, Sundaram KR. A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis of variceal bleeding. Eur J Gastroenterol Hepatol 1996;8:337-342
165. Lay CS, Tsai YT, Teg CY, et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology 1997;25: 1346-1350
166. Harry R, Wendon J. Management of variceal bleeding. Curr Opin Crit Care 2002;8:164-170
167. Chojkier M, Conn HO. Esophageal tamponade in the treatment of bleeding varices: a decadel progress report. Dig Dis Sci 1980;25:267-272
168. Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997;112:889-898
169. Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996;111:138-146
170. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for Trends Pharmacol Sci: results of a randomized study. Gastroenterology 2004;126:469-475
171. Rossi P, Salvatori FM, Fanelli F, et al. Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Radiology 2004;231:820-830
172. Ockenga J, Kroencke TJ, Schuetz T, et al. Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents. Scand J Gastroenterol 2004;39:994-999
173. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996;23:1084-1092
174. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289:217-222
175. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-1976
176. Madoff DC, Ferez-Young IV, Wallace MJ, Skolkin MD, Toombs BD. Management of Trends Pharmacol Sci-related refractory hepatic encephalopathy with reduced Wallgraft endoprostheses. J Vasc Interv Radiol 2003;14:369-374
177. Kerlan RK Jr, LaBerge JM, Baker EL, et al. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 1995;6:917-921
178. Shioyama Y, Matsueda K, Horihata K, et al. Post-Trends Pharmacol Sci hepatic encephalopathy treated by occlusion balloon-assisted retrograde embolization of a coexisting spontaneous splenorenal shunt. Cardiovasc Intervent Radiol 1996;19:53-55
179. Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995;108:1828-1834
180. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998;27:1207-1212
181. Soriano G, Guarner C, Tomas A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992;103:1267-1272
182. Blaise M, Pateron D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1994;20(1 Pt 1):34-38
183. Hsieh WJ, Lin HC, Hwang SJ, et al. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol 1998;93:962-966
184. Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Levy VG. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996;24:802-806
185. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29:1655-1661
186. Toledo C, Salmeron JM, Rimola A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993;17:251-257
187. Folio A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-1501
188. Navasa M, Folio A, Filella X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27:1227-1232
189. Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology 1993;17:1081-1085
190. Llovet JM, Bartoli R, March F, et al. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J Hepatol 1998;28:307-313
191. Tito L, Rimola A, Gines P, Llach J, Arroyo V, Rodes J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988;8:27-31
192. Andreu M, Sola R, Sitges-Serra A, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104;1133-1138
193. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986;91:1343-1346
194. Conn HO. Spontaneous peritonitis and bacteremia in Laennec's cirrhosis caused by enteric organisms. A relatively common but rarely recognized syndrome. Ann Intern Med 1964;60:568-580
195. Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin Liver Dis 1997;17:203-217
196. McHutchison J, Runyon BA. Spontaneous bacterial peritonitis. In: Surawicz CM, Owen R, eds. Gastrointestinal and Hepatic Infections. Philadelphia, PA: WB Saunders; 1994: 455-475
197. Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. Hepatology 1984;4:1209-1211
198. Chu CM, Chang KY, Liaw YF. Prevalence and prognostic significance of bacterascites in cirrhosis with ascites. Dig Dis Sci 1995;40:561-565
199. Cabrera J, Arroyo V, Ballesta AM, et al. Aminoglycoside nephrotoxicity in cirrhosis: value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982;82: 97-105
200. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985;5:457-462
201. Runyon BA, McHutchison JG, Antilion MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis: a randomized controlled study of 100 patients. Gastroenterology 1991;100:1737-1742
202. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409
203. Fernandez J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005;42:627-634
204. Ochs A, Rossle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995;332:1192-1197
205. Choudhury J, Sanyal AJ. Treatment of ascites. Curr Treat Options Gastroenterol 2003;6:481-491
206. Luca A, Garcia-Pagan JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995; 22:753-758
207. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001; 49:729-737
208. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-1654
209. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362:1819-1827
210. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-176
211. Moller S, Bendtsen F, Henriksen JH. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Scand J Gastroenterol 2005;40:491-500
212. Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin Liver Dis 1994;14: 71-81
213. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002;122:1658-1676
214. Maurizio R, Eugenio C, Roberte PR. Results of sclerotherapy for bleeding esophageal varices in patients with schistosomal liver disease: a retrospective study. Hepatogastroenterology 2000;47:424-428
215. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36(4 Pt 1):941-948
216. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-1697
217. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and Trends Pharmacol Sci in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64
218. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871
219. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7:567-580
220. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96